Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors

Kristine K. Deibler, Gary E Schiltz, Matt Clutter, Rama K Mishra, Purav P. Vagadia, Matthew O'Connor, Mariam Donny George, Ryan Gordon, Graham Fowler, Raymond Bergan, Karl A Scheidt

Research output: Contribution to journalArticle

Abstract

Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

Original languageEnglish (US)
Pages (from-to)615-620
Number of pages6
JournalChemMedChem
Volume14
Issue number6
DOIs
StatePublished - Mar 22 2019

Fingerprint

MAP Kinase Kinase 4
Benzoic Acid
Molecular modeling
Oncology
p38 Mitogen-Activated Protein Kinases
Prostatic Neoplasms
Phosphotransferases
Neoplasm Metastasis
mitogen-activated protein kinase kinase kinase 12

Keywords

  • MEK4
  • antitumor agents
  • indazoles
  • kinases
  • prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Deibler, Kristine K. ; Schiltz, Gary E ; Clutter, Matt ; Mishra, Rama K ; Vagadia, Purav P. ; O'Connor, Matthew ; George, Mariam Donny ; Gordon, Ryan ; Fowler, Graham ; Bergan, Raymond ; Scheidt, Karl A. / Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors. In: ChemMedChem. 2019 ; Vol. 14, No. 6. pp. 615-620.
@article{1b6c9cb18468475d916ed61dea27db97,
title = "Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors",
abstract = "Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.",
keywords = "MEK4, antitumor agents, indazoles, kinases, prostate cancer",
author = "Deibler, {Kristine K.} and Schiltz, {Gary E} and Matt Clutter and Mishra, {Rama K} and Vagadia, {Purav P.} and Matthew O'Connor and George, {Mariam Donny} and Ryan Gordon and Graham Fowler and Raymond Bergan and Scheidt, {Karl A}",
year = "2019",
month = "3",
day = "22",
doi = "10.1002/cmdc.201900019",
language = "English (US)",
volume = "14",
pages = "615--620",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

Deibler, KK, Schiltz, GE, Clutter, M, Mishra, RK, Vagadia, PP, O'Connor, M, George, MD, Gordon, R, Fowler, G, Bergan, R & Scheidt, KA 2019, 'Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors' ChemMedChem, vol. 14, no. 6, pp. 615-620. https://doi.org/10.1002/cmdc.201900019

Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors. / Deibler, Kristine K.; Schiltz, Gary E; Clutter, Matt; Mishra, Rama K; Vagadia, Purav P.; O'Connor, Matthew; George, Mariam Donny; Gordon, Ryan; Fowler, Graham; Bergan, Raymond; Scheidt, Karl A.

In: ChemMedChem, Vol. 14, No. 6, 22.03.2019, p. 615-620.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors

AU - Deibler, Kristine K.

AU - Schiltz, Gary E

AU - Clutter, Matt

AU - Mishra, Rama K

AU - Vagadia, Purav P.

AU - O'Connor, Matthew

AU - George, Mariam Donny

AU - Gordon, Ryan

AU - Fowler, Graham

AU - Bergan, Raymond

AU - Scheidt, Karl A

PY - 2019/3/22

Y1 - 2019/3/22

N2 - Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

AB - Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

KW - MEK4

KW - antitumor agents

KW - indazoles

KW - kinases

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85061825418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061825418&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201900019

DO - 10.1002/cmdc.201900019

M3 - Article

VL - 14

SP - 615

EP - 620

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 6

ER -